GWQ ServicePlus AG
Germany · 137 open tenders · 2,776 documented awards
Current tenders
Conclusion of non-exclusive discount agreements pursuant to § 130a paragraph 8 SGB V with the active ingredient mycophenolic acid in the dosage form PSE.
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient Doxylamine 6.96 mg / Pyridoxin 8.23 mg HVW (Cariban)
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a (8) SGB V from 01.07.2025
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V with the active ingredient combination adapalene + benzoyl peroxide
Deadline 10 Nov ·
Conclusion of a Non-Exclusive Discount Agreement pursuant to § 130a para. 8 SGB V for the Active Ingredient Guselkumab
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V with the active ingredient glatiramer acetate
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient Adalimumab
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient Aflibercept in the strength 40mg/ml
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a (8) SGB V for the period from 01.05.2025 to 31.12.2026
Deadline 10 Nov ·
Conclusion of non-exclusive rebate agreements pursuant to § 130 a (8) SGB V for the period 01.01.2025 - 31.12.2026
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V for the period from 01.03.2025 to 31.12.2026
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V with the active substance oxybutynin in the pharmaceutical form PFT
Deadline 10 Nov ·
Conclusion of non-exclusive rebate agreements pursuant to § 130 a (8) SGB V with the active ingredient glatiramer acetate
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a (8) SGB V for contracts of biosimilar active substances
Deadline 10 Nov ·
Conclusion of non-exclusive rebate agreements pursuant to § 130a (8) SGB V for biosimilar active substance contracts
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a (8) SGB V with the active substance Aflibercept in the strength 40mg/ml
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a (8) SGB V from 01.07.2025
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130a (8) SGB V from 01.07.2025
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a (8) SGB V with the active ingredient Oxybutynin in the pharmaceutical form PFT
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V in the period from 01.05.2025 to 31.12.2026
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient combination Adapalene + Benzoyl Peroxide
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V from 01.03.2025 to 31.12.2026
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient mycophenolic acid in the dosage form PSE.
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreement pursuant to § 130a (8) SGB V for the active ingredient guselkumab
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V for the period 01.01.2025 - 31.12.2026
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient Doxylamine 6.96 mg / Pyridoxin 8.23 mg HVW (Cariban)
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient Adalimumab
Deadline 10 Nov ·
Conclusion of non-exclusive discount agreements pursuant to § 130a(8) SGB V for combination preparations from 01.05.2025
Deadline 10 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a (8) SGB V Specialist lot unassigned
Deadline 10 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V as of 01.02.2026
Deadline 10 Dec ·
Purchasing rhythm
Awards per year — who knows the rhythm prepares before the notice appears.
2018156
2019156
2020211
2021251
2022280
2023353
2024366
2025301
2026156
Clement What the numbers say about this buyer
- 85% of this buyer's awards went to companies that had already won here before (1,822 awards since 2017, spread over 272 companies). That is well above the national norm (45%) — newcomers have a harder time here than elsewhere.n = 1,822 awards since 2017
- 35% of the bids received came from small and medium-sized enterprises (17 procedures with a bid mix). Country: 75%.n = 17
- The median procedure drew 3 bids (1,783 procedures with a bid count); 45% ended with a single bidder. Country: median 3.1 bids.n = 1,783
- Across 70 procedures with structured selection criteria, this buyer most often required: Quality management (3 of 70), Security of supply required (1 of 70).n = 70
- 6% of the bids received came from other countries (17 procedures with a bid mix) — all bidders, not just the winners. Country: 3%.n = 17
- Not one of the 1,822 awards with a known winner country has gone to a foreign company so far. National average: 1%.n = 1,822
- From notice to award takes a median 90 days here (263 procedures). Country: 91 days.n = 263
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Expected next awards
From the rhythm of past awards per sector — an expectation, not an announcement. Hit rate so far: 26% of 11,200 closed expectation windows produced a notice.
- Oct 2026Medical equipment & pharma
about every 1 months · 1821 awards · last Sept 2026 to ITF Pharma GmbH
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Hexal AG · Holzkirchen | 68 | 2011–2026 |
| Aristo Pharma GmbH · Berlin | 55 | 2011–2026 |
| kohlpharma GmbH · Merzig | 54 | 2016–2023 |
| neuraxpharm Arzneimittel GmbH · Langenfeld | 50 | 2011–2026 |
| ratiopharm GmbH | 49 | 2015–2026 |
| betapharm Arzneimittel GmbH · Augsburg | 45 | 2011–2026 |
| Micro Labs GmbH · Frankfurt am Main | 45 | 2016–2026 |
| Zentiva Pharma GmbH · Frankfurt am Main | 43 | 2015–2026 |
| PUREN Pharma GmbH & Co. KG · München | 42 | 2016–2026 |
| TAD Pharma GmbH · Cuxhaven | 41 | 2011–2026 |
From 18.0M documented awards · regular winners know this buyer's requirements — that is your competition.